Perspective: Why certain vaccines have been delayed or not developed at all - Manufacturers, regulatory bodies, and even public health authorities often impede the flow of needed vaccines

Health Affairs

Volumn 24, Issue 3, 2005, Pages 631-634

  Plotkin, Stanley A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FUJIAN FLU VACCINE; INFLUENZA VACCINE; LYME DISEASE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ASTHMA; CLINICAL TRIAL; CONGENITAL DISORDER; DEVELOPING COUNTRY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; HUMAN; INFLUENZA; INFLUENZA VIRUS; LICENSING; MEDICAL RESEARCH; NONHUMAN; PREGNANCY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SIDE EFFECT; STREPTOCOCCUS AGALACTIAE; THEORETICAL STUDY; VIRUS STRAIN; WHEEZING; ARTICLE; DRUG APPROVAL; ECONOMICS; GOVERNMENT REGULATION; LEGAL ASPECT; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH SERVICE; UNITED STATES;

DEVELOPING COUNTRIES; DRUG APPROVAL; DRUG INDUSTRY; GOVERNMENT REGULATION; PUBLIC HEALTH ADMINISTRATION; UNITED STATES; VACCINES;

EID: 20044365108     PISSN: 02782715     EISSN: None     Source Type: Journal    
DOI: 10.1377/hlthaff.24.3.631     Document Type: Review

References (13)

1. S.A. Plotkin, "Vaccines, Vaccination, and Vaccinology," Journal of Infectious Diseases 187, no. 9 (2003): 1349-1359.
2. P.A. Offit, "Why Are Pharmaceutical Companies Gradually Abandoning Vaccines?" Health Affairs 24, no. 3 (2005): 622-630.
3. R.T. Mahoney, A. Pablos-Mendez, and S. Ramachandran, "The Introduction of New Vaccines into Developing Countries: III. The Role of Intellectual Property," Vaccine 22, no. 5-6 (2004): 786-792.
4. T. Palker et al., "Protective Efficacy of Intranasal Cold-Adapted Influenza A/New Caledonia/20/99 (H1N1) Vaccines Comprised of Egg- or Cell Culture-Derived Reassortants," Virus Research 105, no. 2 (2004): 183-204.
5. C.B. Bridges et al., "Prevention and Control of Influenza," Morbidity and Mortality Weekly Report 52, no. RR08 (2003): 1-34.
6. "Assessment of the Effectiveness of the 2003-04 Influenza Vaccine among Children and Adults - Colorado, 2003," Morbidity and Mortality Weekly Report 53, no. 31 (2004): 707-710.
7. R.B. Belshe et al., "The Efficacy of Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenzavirus Vaccine in Children," New England Journal of Medicine 338, no. 20 (1998): 1405-1412.
8. R. Bergen et al., "Safety of Cold-Adapted Live Attenuated Influenza Vaccine in a Large Cohort of Children and Adolescents," Pediatric Infectious Discase Journal 23, no. 2 (2004): 138-144.
9. "Lyme Disease - United States, 2001-2002," Morbidity and Mortality Weekly Report 53, no. 17 (2004): 359-381.
10. "Recommendations for the Use of Lyme Disease Vaccine," Morbidity and Mortality Weekly Report 48, no. RR-7 (1999): 1-25.
11. K.R. Stratton, J.S. Durch, and R.S. Lawrence, eds., Vaccines for the Twenty-first Century (Washington: National Academies Press, 2000).
12. R.I. Glass et al., "The Future of Rotavirus Vaccines: A Major Setback Leads to New Opportunities," Lancet 363, no. 9420 (2004): 1547-1550;
13. and T.V. Murphy et al., "The First Rotavirus Vaccine and Intussusception: Epidemiological Studies and Policy Decisions," Journal of Infectious Disease 187, no. 8 (2003): 1309-1313.